Health Catalyst, Inc. (NASDAQ:HCAT) Insider Linda Llewelyn Sells 2,005 Shares

Health Catalyst, Inc. (NASDAQ:HCAT) insider Linda Llewelyn sold 2,005 shares of the stock in a transaction on Monday, April 15th. The shares were sold at an average price of $6.11, for a total value of $12,250.55. Following the transaction, the insider now directly owns 126,226 shares in the company, valued at $771,240.86. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Health Catalyst Price Performance

NASDAQ HCAT opened at $5.63 on Thursday. Health Catalyst, Inc. has a 12 month low of $5.51 and a 12 month high of $14.37. The company has a debt-to-equity ratio of 0.62, a current ratio of 4.42 and a quick ratio of 4.42. The stock’s 50 day moving average is $7.96 and its 200 day moving average is $8.46.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings data on Thursday, February 22nd. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.06. The business had revenue of $75.08 million during the quarter, compared to the consensus estimate of $73.67 million. Health Catalyst had a negative net margin of 39.92% and a negative return on equity of 12.19%. On average, research analysts expect that Health Catalyst, Inc. will post -0.47 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on HCAT shares. Piper Sandler reiterated an “overweight” rating and set a $15.00 price objective (down previously from $17.00) on shares of Health Catalyst in a research report on Friday, February 23rd. Barclays began coverage on shares of Health Catalyst in a research report on Wednesday, January 3rd. They set an “overweight” rating and a $14.00 price target for the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $16.00 price objective on shares of Health Catalyst in a report on Wednesday, April 10th. Evercore ISI reduced their target price on shares of Health Catalyst from $11.00 to $10.00 and set an “outperform” rating for the company in a report on Friday, February 23rd. Finally, Guggenheim upgraded shares of Health Catalyst from a “neutral” rating to a “buy” rating and set a $14.00 price target on the stock in a research report on Friday, January 26th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $12.10.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Fairfield Bush & CO. bought a new stake in Health Catalyst in the first quarter worth $25,000. Point72 Hong Kong Ltd bought a new stake in shares of Health Catalyst in the 1st quarter worth about $33,000. Macquarie Group Ltd. purchased a new stake in shares of Health Catalyst during the 2nd quarter valued at about $26,000. Tower Research Capital LLC TRC lifted its holdings in shares of Health Catalyst by 165.1% in the 3rd quarter. Tower Research Capital LLC TRC now owns 3,118 shares of the company’s stock valued at $32,000 after acquiring an additional 1,942 shares during the last quarter. Finally, Advisor Group Holdings Inc. lifted its holdings in shares of Health Catalyst by 86.3% in the 1st quarter. Advisor Group Holdings Inc. now owns 5,324 shares of the company’s stock valued at $137,000 after acquiring an additional 2,467 shares during the last quarter. 85.00% of the stock is currently owned by institutional investors.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.